We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Kinase Inhibitor Online Database Will Assist Drug Developers

By LabMedica International staff writers
Posted on 14 Nov 2011
A recent paper described the establishment of a free on-line database that will allow drug developers to analyze the complex interactions between kinases and their inhibitors, which will aid in developing cancer drugs that block specific disease-related kinases while avoiding major adverse side effects.

Investigators at the Fox Chase Cancer Center (Philadelphia, PA, USA) have cataloged and cross-indexed the actions of 178 candidate drugs capable of blocking the activity of one or more of 300 kinases. More...
Among these enzymes are many that have been linked to the development of cancer and other diseases.

Quantitative analyses reported in the October 30, 2011, online edition of the journal Nature Biotechnology revealed complex and often unexpected interactions between protein kinases and kinase inhibitors, with a wide spectrum of promiscuity.

“These results have pushed the field closer to finding truly specific inhibitors of the processes that drive cancer,” said senior author Dr. Jeffrey R. Peterson, associate professor of cancer biology at the Fox Chase Cancer Center. “We now have a collection of kinase inhibitors that are better characterized and understood than any other library. The next step is to use this information to identify specific, effective therapies that stop cancer in its tracks while avoiding healthy processes.”

“The fact that kinase inhibitors target multiple kinases may actually be a good thing,” said Dr. Peterson. “It may not be possible to develop a successful drug against one kinase. Indeed, some kinase inhibitors that are effective in cancer are known to target multiple kinases.”

The kinase inhibitor library is available online to the research community at no charge.

Related Links:
Fox Chase Cancer Center



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Hemodynamic System Monitor
OptoMonitor
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.